181 related articles for article (PubMed ID: 35397674)
1. Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.
Li X; Jia Z; Yan Y
Acta Neurochir (Wien); 2022 Aug; 164(8):1985-1993. PubMed ID: 35397674
[TBL] [Abstract][Full Text] [Related]
2. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Zhao B; Wu J; Xia Y; Li H; Wang Y; Qu T; Xing H; Wang Y; Ma W
Pharmacol Res; 2022 Aug; 182():106316. PubMed ID: 35724820
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of tumor treating fields therapy for high-grade gliomas.
Shah PP; White T; Khalafallah AM; Romo CG; Price C; Mukherjee D
J Neurooncol; 2020 Jul; 148(3):433-443. PubMed ID: 32578135
[TBL] [Abstract][Full Text] [Related]
6. Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis.
Jin L; Guo S; Zhang X; Mo Y; Ke S; Duan C
Neurosurg Rev; 2021 Aug; 44(4):1943-1955. PubMed ID: 33037945
[TBL] [Abstract][Full Text] [Related]
7. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
8. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
[TBL] [Abstract][Full Text] [Related]
9. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.
Regev O; Merkin V; Blumenthal DT; Melamed I; Kaisman-Elbaz T
Neurooncol Pract; 2021 Aug; 8(4):426-440. PubMed ID: 34277021
[TBL] [Abstract][Full Text] [Related]
11. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
Fu M; Zhou Z; Huang X; Chen Z; Zhang L; Zhang J; Hua W; Mao Y
BMC Cancer; 2023 Jun; 23(1):544. PubMed ID: 37316802
[TBL] [Abstract][Full Text] [Related]
12. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
14. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
18. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
Mirza FA; Shamim MS
J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
[TBL] [Abstract][Full Text] [Related]
19. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
20. Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review.
Xiang X; Ji Z; Jin J
Radiother Oncol; 2024 Jan; 190():110012. PubMed ID: 37972737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
